Research Study

A PHASE 3 MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826-83) 20 MG OR 80 MG [OR TAFAMIDIS (PF-06291826-00) 61 MG] IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (ATTR-CM)
Principal Investigator 
Margot Davis

Overview

Body Locations and Systems 
Cardiomyopathy
ClinicalTrials.gov# 
NCT02791230
Status 
Closed for Recruitment
Study Start/End 
Apr 29, 2019 to Dec 1, 2024
Locations 
Vancouver General Hospital
Name/Title 
Ngaire Meadows, Research Coordinator
Phone 
604-875-5775
Email Address 
ngaire.meadows2@vch.ca
Purpose of Study 

The purpose of this study is to evaluate tafamidis for the treatment of transthyretin cardiomyopathy.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.